Glemorstart-M V 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, mitigating postprandial hyperglycemia. The synergistic action of these three agents addresses multiple pathophysiological defects in type 2 diabetes, offering improved glycemic control with a reduced risk of hypoglycemia compared to higher doses of individual agents. Glemorstart-M V 2 Tablet SR is indicated as an adjunct to diet and exercise for the management of type 2 diabetes when monotherapy or dual therapy is insufficient. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, and contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to any component.